Skip to content

PTM202 for the Treatment of Environmental Enteric Dysfunction (EED)

Pilot Study of PTM202 for the Treatment of Environmental Enteric Dysfunction (EED)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03263871
Enrollment
200
Registered
2017-08-28
Start date
2017-10-14
Completion date
2019-02-15
Last updated
2019-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Environmental Enteric Dysfunction

Keywords

nutrition

Brief summary

The purpose of this study is to assess the effectiveness of PTM202 in treating environmental enteric dysfunction.

Interventions

DIETARY_SUPPLEMENTPTM202

PTM202 given twice daily for 30 days.

DIETARY_SUPPLEMENTmicro-nutrient sprinkles

Micro-nutrient sprinkles will be given twice daily for 30 days.

Sponsors

International Centre for Diarrhoeal Disease Research, Bangladesh
CollaboratorOTHER
Virginia Commonwealth University
CollaboratorOTHER
University of Virginia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Months to 9 Months
Healthy volunteers
Yes

Inclusion criteria

* Aged 6 - 9 months old * -1\> Weight-for-age Z score \> -3 * Parental consent to participate and receive daily supplementation with either PTM202 and/or micro-nutrient sprinkles, participate in specimen collection

Exclusion criteria

* Presence of known kidney, liver, heart, developmental, or neurologic disease * Allergy to milk and/or egg (assessed by history) * Milk intolerance (assessed by history) * Abnormal liver or kidney function tests * Family is planning to move from the study area or children is enrolled to the other clinical trial within 3 months of follow up * Child being exclusively breast fed at the time of enrollment

Design outcomes

Primary

MeasureTime frameDescription
EED biomarker composite score4 monthscomposite score of fecal Reg 1B, fecal myeloperoxidase, urinary lactulose: mannitol ratio, serum soluable-CD14, and serum C-reactive protein

Secondary

MeasureTime frame
Weight gain4 months
Height gain4 months
Number of diarrheal episodes4 months
Glucose hydrogen breath test4 months

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026